Muy-Kheng M Tea1, Regina Kroiss2, Daniela Muhr3, Christine Fuerhauser-Rappaport3, Peter Oefner4, Teresa M Wagner5, Christian F Singer3. 1. Department of Obstetrics and Gynecology and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. Electronic address: muy-kheng.tea@meduniwien.ac.at. 2. Department of Obstetrics and Gynecology and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Kaiser Franz Josef Hospital, SMZ-Süd, Department of OB/GYN, Vienna, Austria. 3. Department of Obstetrics and Gynecology and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. 4. University of Regensburg, Institute of Functional Genomics, Regensburg, Germany. 5. Kaiser Franz Josef Hospital, SMZ-Süd, Department of OB/GYN, Vienna, Austria.
Abstract
BACKGROUND: Mutations in brca1 and 2 genes lead to a significant increase in the lifetime risk of developing breast (BC) and ovarian cancer (OC). There are indications that birth cohort can influence the cancer risk in brca1 mutation carriers. Therefore, we investigated the risks for BC and OC associated with brca2 mutations in a cohort of female mutation carriers of a genetically heterogeneous Central European population. PATIENTS AND METHODS: This study included 246 women in whom a functional mutation in the brca2 gene had been identified at our institution. At the time of analysis, 153 women had developed cancer (142 BC, 9 OC, 2 BC and OC). Risks were estimated using the product limit method. The log rank test was used to compare different strata. RESULTS: After correction for risk-reducing surgeries, the cumulative risk of developing cancer to age 70 was found to be 88% for BC (95% CI 81-95%) and 31% for OC (95% CI 17-45%). Female brca2 mutation carriers born in 1958 or later were at a significantly higher risk of developing BC at a younger age (p<0.001), while no such age cohort-dependent correlation was found for OC. CONCLUSION: The age cohort-dependent early onset in BC in women born after 1958 strongly suggests the importance of exogenous factors such as lifestyle modification while this does not seem to be the case for OC. Female brca2 mutation carriers should be counseled about their age cohort-dependent breast cancer risk.
BACKGROUND: Mutations in brca1 and 2 genes lead to a significant increase in the lifetime risk of developing breast (BC) and ovarian cancer (OC). There are indications that birth cohort can influence the cancer risk in brca1 mutation carriers. Therefore, we investigated the risks for BC and OC associated with brca2 mutations in a cohort of female mutation carriers of a genetically heterogeneous Central European population. PATIENTS AND METHODS: This study included 246 women in whom a functional mutation in the brca2 gene had been identified at our institution. At the time of analysis, 153 women had developed cancer (142 BC, 9 OC, 2 BC and OC). Risks were estimated using the product limit method. The log rank test was used to compare different strata. RESULTS: After correction for risk-reducing surgeries, the cumulative risk of developing cancer to age 70 was found to be 88% for BC (95% CI 81-95%) and 31% for OC (95% CI 17-45%). Female brca2 mutation carriers born in 1958 or later were at a significantly higher risk of developing BC at a younger age (p<0.001), while no such age cohort-dependent correlation was found for OC. CONCLUSION: The age cohort-dependent early onset in BC in women born after 1958 strongly suggests the importance of exogenous factors such as lifestyle modification while this does not seem to be the case for OC. Female brca2 mutation carriers should be counseled about their age cohort-dependent breast cancer risk.
Authors: Janet R Vos; Li Hsu; Richard M Brohet; Marian J E Mourits; Jakob de Vries; Kathleen E Malone; Jan C Oosterwijk; Geertruida H de Bock Journal: J Clin Oncol Date: 2015-07-06 Impact factor: 44.544
Authors: Christine Staudigl; Georg Pfeiler; Katharina Hrauda; Romana Renz; Andreas Berger; Renate Lichtenschopf; Christian F Singer; Muy-Kheng M Tea Journal: BMC Cancer Date: 2016-07-08 Impact factor: 4.430
Authors: Yuya Kobayashi; Shan Yang; Keith Nykamp; John Garcia; Stephen E Lincoln; Scott E Topper Journal: Genome Med Date: 2017-02-06 Impact factor: 11.117
Authors: Patrick Rump; Omid Jazayeri; Krista K van Dijk-Bos; Lennart F Johansson; Anthonie J van Essen; Johanna B G M Verheij; Hermine E Veenstra-Knol; Egbert J W Redeker; Marcel M A M Mannens; Morris A Swertz; Behrooz Z Alizadeh; Conny M A van Ravenswaaij-Arts; Richard J Sinke; Birgit Sikkema-Raddatz Journal: BMC Med Genomics Date: 2016-02-04 Impact factor: 3.063